Investigating how Ctr9 affects breast cancer treatment response
Ctr9 as a Predictive Biomarker for EZH2 Inhibitor Sensitivity
This study is looking at a protein called Ctr9 to see how it affects breast cancer cells that respond to estrogen, with the hope of finding better ways to treat patients who struggle with treatment resistance.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Wisconsin-Madison NIH-funded |
| Lab location | 1 site (Madison, United States) |
| Project ID | NIH-11075865 on NIH RePORTER |
What this research studies
This research focuses on understanding the role of Ctr9, a protein that influences the identity of breast cancer cells, particularly those that are estrogen receptor-positive. By studying how the depletion of Ctr9 affects these cells, the researchers aim to uncover mechanisms behind treatment resistance in breast cancer. The study utilizes advanced cell line models to observe changes in cell behavior and sensitivity to EZH2 inhibitors, which are drugs that may enhance treatment effectiveness. Patients may benefit from insights that could lead to more personalized and effective therapies for breast cancer.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients with estrogen receptor-positive breast cancer who may be experiencing treatment resistance.
Not a fit: Patients with other types of breast cancer or those not undergoing treatment for breast cancer may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to improved treatment strategies for patients with breast cancer, particularly those who develop resistance to standard therapies.
How similar studies have performed: Previous research has shown promising results in targeting similar pathways in cancer treatment, indicating potential for success in this approach.
Where this research is happening
Madison, United States
- University of Wisconsin-Madison — Madison, United States (Active)
Researchers
- Principal investigator: Xu, Wei — University of Wisconsin-Madison
- Study coordinator: Xu, Wei
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.